retatrutide trial results today Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released phase 2 demonstrating 25% weight loss in half of people with #obesity. This amount of weight loss has not been accomplished Eli Lilly's Retatrutide Phase 3
Description
No GP visit, discreet delivery
The incorporation of GLP-1 medications, coupled with lifestyle modifications, has maximized the reduction of obesity in adults
But as its popularity grows, so do reports of serious gastrointestinal injuriesincluding bowel obstruction and ileus (intestinal paralysis)
Why? Because it delivers astonishing results at an extremely low cost
Its part of a class of drugs called GLP-1 receptor agonists, which help regulate blood sugar and (as a major side effect) can lead to significant weight loss
